Denali Therapeutics (DNLI) Research & Development (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Research & Development data on file, last reported at $103.8 million in Q1 2026.

• Research & Development for Q1 2026 came in at $103.8 million, down 10.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $406.4 million (changed 0.18% YoY), and the FY2025 annual result was $418.8 million, up 5.63% from the prior year.
• Research & Development advanced to $103.8 million in Q1 2026 per DNLI's latest filing, from $97.9 million in the prior quarter.
• Over five years, Research & Development peaked at $128.8 million in Q1 2023 and troughed at $86.1 million in Q1 2022.
• A 5-year average of $100.1 million and a median of $98.2 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2024: Research & Development jumped 49.62% in 2023, then decreased 16.92% in 2024.
• A 5-year view of Research & Development shows it stood at $92.1 million in 2022, then gained by 17.04% to $107.8 million in 2023, then dropped by 7.44% to $99.8 million in 2024, then decreased by 1.89% to $97.9 million in 2025, then increased by 6.07% to $103.8 million in 2026.
• Business Quant data shows DNLI's Research & Development at $103.8 million in Q1 2026, $97.9 million in Q4 2025, and $101.9 million in Q3 2025.